Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting

References

• Herrstedt J. The latest consensus on antiemetics. Curr Opin Oncol. 2018;30(4):233–239. doi: 10.1097/CCO.0000000000000450
   PubMed Web of Science ®Google Scholar
• Jordan K, Chan A, Gralla RJ, et al. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents – updated MASCC/ESMO consensus recommendation. Support Care Cancer. 2024;32(1):53. doi: 10.1007/s00520-023-08220-5
   Web of Science ®Google Scholar
• Moertel CG, Reitemeier RJ, Gage RP. A controlled clinical evaluation of antiemetic drugs. JAMA. 1963;186(2):116–118. doi: 10.1001/jama.1963.03710020036011
   PubMed Web of Science ®Google Scholar
• Bakowsky MT. Advances in anti-emetic therapy. Cancer Treat Rev. 1984;11(3):237–256. doi: 10.1016/0305-7372(84)90010-0
   PubMed Web of Science ®Google Scholar
• Carlsson A, Lindqvist M, Magnusson T. 3,4-dihydroxyphenylalanine and 5-hydroxy-tryptophan as reserpine antagonists. Nature. 1957;180(4596):1200. doi: 10.1038/1801200a0
   PubMed Web of Science ®Google Scholar
• Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature. 1979;277(5692):93–96. doi: 10.1038/277093a0
   PubMed Web of Science ®Google Scholar
• Sibley D, Monsma F. Molecular biology and dopamine receptors. Trends Pharmacol Sci. 1992;13:61–69. doi: 10.1016/0165-6147(92)90025-2
   PubMed Web of Science ®Google Scholar
• Glaviano V, Wang SC. Dual mechanism of anti-emetic action of 10(gamma-dimethylaminopropyl)-2-chlorophenothiazine hydrochloride (chlorpromazine) in dogs. J Pharmacol Exp Ther. 1955;114(3):358–366.
   PubMed Web of Science ®Google Scholar
• Darmani NA, Zhao W, Ahmad B. The role of D2 and D3 dopamine receptors in the mediation of emesis in Cryptotis parva (the least shrew). J Neural Transm. 1999;106(11–12):1045–1061. doi: 10.1007/s007020050222
   PubMed Web of Science ®Google Scholar
• Stemp G, Ashmeade T, Branch CL, et al. Design and Synthesis of trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): a potent and selective dopamine D3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J Med Chem. 2000;43(9):1878–1885. doi: 10.1021/jm000090i
   PubMed Web of Science ®Google Scholar
• Pinder RM, Brigden RN, Sawyer PR, et al. Metoclopramide: a review of its pharmacological properties and clinical use. Drugs. 1976;12(2):81–131. doi: 10.2165/00003495-197612020-00001
   PubMed Web of Science ®Google Scholar
• Schulze-Delrieu K. Metoclopramide. Gastroenterology. 1979;77:768–779. doi: 10.1016/0016-5085(79)90236-1
   PubMed Web of Science ®Google Scholar
• Justin-Besancon L, Laville C, Thominet M. Le métoclopramideetses homologues. Introduction à leurétudebiologigue. CR AcadSci (Paris). 1964;258:4384–4386.
   PubMedGoogle Scholar
• Graffner C, Lagerstrom PO, Lundborg P, et al. Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. Br J Clin Pharmacol. 1979;8(5):469–474. doi: 10.1111/j.1365-2125.1979.tb01028.x
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Metoclopramide orally disintegrating tablets. n.d. [cited 2023 Oct 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021793lbl.pdf
   Google Scholar
• Lee A, Kuo B. Metoclopramide in the treatment of diabetic gastroparesis. Expert Rev Endocrinol Metab. 2010;5(5):653–662. doi: 10.1586/eem.10.41
   PubMedGoogle Scholar
• Mikami H, Ishimura N, Fukazawa K, et al. Effects of metoclopramide on esophageal motor activity and esophagogastric junction compliance in healthy volunteers. J Neurogastroenterol Motil. 2016;22(1):112–117. doi: 10.5056/jnm15130
   PubMed Web of Science ®Google Scholar
• Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981;305(16):905–909. doi: 10.1056/NEJM198110153051601
   PubMed Web of Science ®Google Scholar
• Miner WD, Sanger GJ. Inhibition of cisplatin-induced nausea and vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 1986;88(3):497–499. doi: 10.1111/j.1476-5381.1986.tb10228.x
   PubMed Web of Science ®Google Scholar
• Moertel C, Reitemeier RJ. Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology. 1969;57(3):262–268. doi: 10.1016/S0016-5085(19)33898-3
   PubMed Web of Science ®Google Scholar
• Arnold DJ, Ribiero V, Bulkin W. Metoclopramide versus prochlorperazine in the prevention of vomiting from cisdiamminedichloroplatinum. Proc Am Soc Clin Oncol. 1980;21:344.
   Google Scholar
• Frytak S, Moertel CG, Eagan RT, et al. A double-blind comparison of metoclopramide and prochlorperazine as antiemetics for platinum therapy. Proc Am Soc Clin Oncol. 1981;22:421.
   Google Scholar
• Kahn T, Elias EG, Mason GR. A single dose of metoclopramide in the control of vomiting from cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep. 1978;7:1106–1107.
   Google Scholar
• Herrstedt J, Aproo MS, Smyth JF, et al. Corticosteroids, dopamine antagonists and other drugs. Supportive Care Cancer. 1998;6(3):204–214. doi: 10.1007/s005200050155
   PubMed Web of Science ®Google Scholar
• Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989;7(1):108–114. doi: 10.1200/JCO.1989.7.1.108
   PubMed Web of Science ®Google Scholar
• Roila F, Ruggeri B, Ballatori E, et al. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Annals Oncol. 2015;26(6):1248–1253. doi: 10.1093/annonc/mdv132
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. on behalf of the participants of the MASCC/ESMO Consensus Conference 2022. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open 2024; published online January 11. 2023. doi: 10.1016/j.esmoop.2023.102195
   Google Scholar
• Grunberg SM, Ehler E, Je M, et al. Oral metoclopramide with or without diphenhydramine: potential for prevention of late nausea and vomiting induced by cisplatin. J Natl Cancer Inst. 1988;80(11):864–868. doi: 10.1093/jnci/80.11.864
   PubMedGoogle Scholar
• Isola S, Hussain A, Dua A, et al. Metoclopramide. StatPearls [Internet]. 2023 Sep 4 [cited 2023 Oct 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519517/
   Google Scholar
• European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. 2013 Dec 20 [cited 2024 Jun 20].Available from: https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-changes-use-metoclopramide
   Google Scholar
• Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 Receptor Antagonist with Both Presynaptic and Limbic Selectivity. J Pharmacol Exp Ther. 1997;280:83–97.
   PubMed Web of Science ®Google Scholar
• Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian): a review of 11 clinical studies. International Clinical Psychopharmacology. 1999;14(4):209–218. doi: 10.1097/00004850-199907000-00002
   PubMed Web of Science ®Google Scholar
• Zhang L-F, Zhang C-F, Tang W-X, et al. Efficacy of amisulpride on postoperative nausea and vomiting: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020;76(7):903–912. doi: 10.1007/s00228-020-02869-1
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Lindberg S, Petersen PC. Prevention of chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes. Drugs Aging. 2022;39(1):1–21. doi: 10.1007/s40266-021-00909-8
   PubMed Web of Science ®Google Scholar
• Rosenzweig P, Canal M, Patat A, et al. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002;17(1):1–13. doi: 10.1002/hup.320
   PubMed Web of Science ®Google Scholar
• Fox GM, Roffel AF, Hartstra J, et al. Metabolism and excretion of intravenous, radio-labeled amisulpride in healthy, adult volunteers. Clin Pharmacol 2019;11:161–169. doi: 10.2147/CPAA.S234256
   PubMed Web of Science ®Google Scholar
• Smyla N, Koch T, Eberhart LHJ, et al. An overview of intravenous amisulpride as a new therapeutic option for the prophylaxis and treatment of postoperative nausea and vomiting. Expert Opin Pharmacother. 2020;21(5):517–522. doi: 10.1080/14656566.2020.1714029
   PubMed Web of Science ®Google Scholar
• Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757–777. doi: 10.2147/TCRM.S117321
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Summers Y, Daugaard G, et al. Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study. Support Care Cancer. 2018;26(1):139–145. doi: 10.1007/s00520-017-3825-2
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Summers Y, Jordan K, et al. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled, dose-ranging trial. Support Care Cancer. 2019;27(7):2699–2705. doi: 10.1007/s00520-018-4564-8
   PubMed Web of Science ®Google Scholar
• Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerability of antipsychotics: focus on amisulpride. Drug Healthcare Patient Saf. 2010;2:205. doi: 10.2147/DHPS.S6226
   PubMedGoogle Scholar
• Rein W, Coulouvrat C, Dondey-Nouvel L. Safety profile of amisulpride in short‐ and long‐term use. Acta Psychiatr Scand. 2003;101(400):23–27. doi: 10.1111/j.0065-1591.2000.007s021[dash]5.x
   Google Scholar
• Herrstedt J, Jørgensen M, Angelo HR. The effect of food on serum concentrations of metopimazine. Br J Clin Pharmacol. 1990;30(2):237–243. doi: 10.1111/j.1365-2125.1990.tb03770.x
   PubMed Web of Science ®Google Scholar
• Croom KF, Keating GM. Metopimazine. Am J Cancer. 2006;5(2):123–136. doi: 10.2165/00024669-200605020-00006
   Google Scholar
• Herrstedt J, Hyttel J, Pedersen J. Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D2, 5-hydroxytryptamine3, histamine H1, muscarine cholinergic and ?1 receptors. Cancer Chemother Pharmacol. 1993;33(1):53–56. doi: 10.1007/BF00686023
   PubMed Web of Science ®Google Scholar
• Jolliet P, Nion S, Allain-Veyrac G, et al. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood–brain barrier. Pharmacol Res. 2007;56(1):11–17. doi: 10.1016/j.phrs.2006.12.004
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Sigsgaard T, Handberg J, et al. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol. 1997;15(4):1690–1696. doi: 10.1200/JCO.1997.15.4.1690
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Sigsgaard T, Boesgaard M, et al. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med. 1993;328(15):1076–1080. doi: 10.1056/NEJM199304153281502
   PubMed Web of Science ®Google Scholar
• Sigsgaard T, Herrstedt J, Handberg J, et al. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol. 2001;19(7):2091–2097. doi: 10.1200/JCO.2001.19.7.2091
   PubMed Web of Science ®Google Scholar
• Sigsgaard T, Herrstedt J, Andersen LJ, et al. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. Br J Cancer. 1999;80(3–4):412–418. doi: 10.1038/sj.bjc.6690372
   PubMed Web of Science ®Google Scholar
• Sigsgaard T, Herrstedt J, Christensen P, et al. Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D2 antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapy. Support Care Cancer. 2000;8(3):233–237. doi: 10.1007/s005200050291
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Sigsgaard TC, Nielsen HA, et al. Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Support Care Cancer. 2007;15(4):417–426. doi: 10.1007/s00520-006-0158-y
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Sigsgaard T, Angelo HR, et al. Dose-finding study of oral metopimazine. Support Care Cancer. 1997;5(1):38–43. doi: 10.1007/BF01681960
   PubMed Web of Science ®Google Scholar
• Din L, Preuss CV. Prochlorperazine. StatPearls. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
   Google Scholar
• Prochlorperazine. AA Pharma Inc. 2012 Aug 31 [cited2023 Oct 19]. Available from: https://www.aapharma.ca/downloads/en/PIL/Prochlorazine_PI.pdf
   Google Scholar
• Isah AO, Rawlins MD, Bateman DN. Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol. 1991;32(6):677–684. doi: 10.1111/j.1365-2125.1991.tb03973.x
   PubMed Web of Science ®Google Scholar
• Taylor WB, Bateman DN. Preliminary studies of the pharmacokinetics and pharmacodynamics of prochlorperazine in healthy volunteers. Br J Clin Pharmacol. 1987;23(2):137–142. doi: 10.1111/j.1365-2125.1987.tb03021.x
   PubMed Web of Science ®Google Scholar
• Finn A, Collins J, Voyksner R, et al. Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route. J Clin Pharmacol. 2005;45(12):1383–1390. doi: 10.1177/0091270005281044
   PubMed Web of Science ®Google Scholar
• Hempel C, Norenberg W, Sobottka H, et al. The phenothiazine-class antipsychotic drugs prochlorperazine and trifluoperazine are potent allosteric modulators of the human P2X7 receptor. Neuropharmacol. 2013;75:365–379. doi: 10.1016/j.neuropharm.2013.07.027
   PubMed Web of Science ®Google Scholar
• Ison PJ, Peroutka SJ. Neurotransmitter receptor binding studies predict antiemetic efficacy and side effects. Cancer Treat Rep. 1986;70(5):637–641.
   PubMedGoogle Scholar
• Obara K, Horiguchi S, Shimada T, et al. Characterization of binding of antipsychotics to muscarinic receptors using mouse cerebral cortex. J Pharmacol Sci. 2019;140(2):197–200. doi: 10.1016/j.jphs.2019.05.006
   PubMed Web of Science ®Google Scholar
• Olver IN, Wolf M, Laidlaw C, et al. A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy. Eur J Cancer. 1992;28A(11):1798–1802. doi: 10.1016/0959-8049(92)90006-N
   PubMed Web of Science ®Google Scholar
• Hickok JT, Roscoe JA, Morrow GR, et al. 5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol. 2005;6(10):765–772. doi: 10.1016/S1470-2045(05)70325-9
   PubMed Web of Science ®Google Scholar
• Lindley C, Goodin S, McCune J, et al. Prevention of delayed chemotherapy-induced nausea and vomiting after moderately high to highly emetogenic chemotherapy: comparison of ondansetron, prochlorperazine, and dexamethasone. Am J Clin Oncol. 2005;28(3):270–276. doi: 10.1097/01.coc.0000145983.35929.2a
   PubMed Web of Science ®Google Scholar
• Jm J, Qin R, Bardia A, et al. Antiemetics for chemotherapy-induced nausea and vomiting occurring despite prophylactic antiemetic therapy. J Pall Med. 2011;14(7):810–814. doi: 10.1089/jpm.2011.0058
   PubMed Web of Science ®Google Scholar
• Caughey GE, Roughead EE, Pratt N, et al. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf. 2010;19:977–982. doi: 10.1002/pds.2009
   PubMed Web of Science ®Google Scholar
• McGrane I, Spina E, Hiemke C, et al. Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis. Expert Opin Drug Metab Toxicol. 2022;18(2):135–149. doi: 10.1080/17425255.2022.2057297
   PubMed Web of Science ®Google Scholar
• Prommer E. Role of haloperidol in palliative medicine: an update. Am J Hospice Pall Med. 2012;29(4):295–301. doi: 10.1177/1049909111423094
   PubMed Web of Science ®Google Scholar
• Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet. 1999;37(6):435–456. doi: 10.2165/00003088-199937060-00001
   PubMed Web of Science ®Google Scholar
• Magliozzi JR, Hollister LE. Elimination half-life and bioavailability of haloperidol in schizophrenic patients. J Clin Psychiatry. 1985;46(1):20–21.
   PubMed Web of Science ®Google Scholar
• Tyler MW, Zaldivar-Diez J, Haggarty SJ. Classics in chemical neuroscience: haloperidol. ACS Chem Neurosci. 2017;8(3):444–453. doi: 10.1021/acschemneuro.7b00018
   PubMed Web of Science ®Google Scholar
• Carpenter Jt SL, Wheeler JR, Lee J, et al. A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. J Clin Oncol. 1988;6(9):1397–1400. doi: 10.1200/JCO.1988.6.9.1397
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Gala KV, Lampenfeld M, et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a Randomized Double-blind crossover study. J Clin Oncol. 1984;2(7):782–787. doi: 10.1200/JCO.1984.2.7.782
   PubMed Web of Science ®Google Scholar
• Dulal S, Paudel BD, Neupane P, et al. Randomized phase II trial to compare the efficacy of haloperidol and olanzapine in the control of chemotherapy-induced nausea and vomiting in Nepal. J Glob Oncol. 2019;2019(5):1–6. doi: 10.1200/JGO.18.00245
   Google Scholar
• NCCN Guidelines Version 1. Antiemesis. 2024 [cited 2024 Jan 3]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
   Google Scholar
• Pham A, Lee JY, Miller CWT. Acute Extrapyramidal Side Effects from Smoked Haloperidol. Case Rep Psychiatry. 2021:4177263. doi: 10.1155/2021/4177263
   PubMedGoogle Scholar
• Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today. 2003;39(7):551–557. doi: 10.1358/dot.2003.39.7.799445
   PubMed Web of Science ®Google Scholar
• Pisani F, Oteri G, Costa C, et al. Effects of psychotropic drugs on seizure threshold. Drug Saf. 2002;25(2):91–110. doi: 10.2165/00002018-200225020-00004
   PubMed Web of Science ®Google Scholar
• Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Ther. 2010;32(3):472–491. doi: 10.1016/j.clinthera.2010.03.003
   PubMed Web of Science ®Google Scholar
• Zirker W, Dorokhine I, Knapp CM, et al. Haloperidol overdosing in the treatment of agitated hospitalized older people with delirium: a retrospective chart review from a community teaching hospital. Drugs Aging. 2013;30(8):639–644. doi: 10.1007/s40266-013-0087-7
   PubMed Web of Science ®Google Scholar
• James Adams. Emergency Medicine. 2nd ed. W.B. Saunders; 2013. doi: 10.1016/B978-1-4377-3548-2.00195-6
   Google Scholar
• Foo LK, Duffull SB, Calver L, et al. Population pharmacokinetics of intramuscular droperidol in acutely agitated patients. Br J Clin Pharmacol. 2016;82(6):1550. doi: 10.1111/bcp.13093
   PubMed Web of Science ®Google Scholar
• McKeage K, Simpson D, Wagstaff AJ. Intravenous droperidol. A review of its use in the management of postoperative nausea and vomiting. Drugs. 2006;66(16):2123–2147. doi: 10.2165/00003495-200666160-00009
   PubMed Web of Science ®Google Scholar
• Lehmann KA, Van Peer A, Ikonomakis M, et al. Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia. Br J Anaesth. 1988;61(3):297–301. doi: 10.1093/bja/61.3.297
   PubMed Web of Science ®Google Scholar
• Flood P, Coates KM. Droperidol Inhibits GABA and Neuronal Nicotinic Receptor Activation. Anesthesiology. 2002;96(4):987–993. doi: 10.1097/00000542-200204000-00029
   PubMed Web of Science ®Google Scholar
• Grossman B, Lessin LS, Cohen P. Droperidol Prevents Nausea and Vomiting from cis-Platinum. N Engl J Med. 1979;301:47.
   PubMed Web of Science ®Google Scholar
• Stuart-Harris R, Buckman R, Starke I, et al. Chlorpromazine, placebo and droperidol in the treatment of nausea and vomiting associated with cisplatin therapy. Postgrad Med J. 1983;59(694):500–503. doi: 10.1136/pgmj.59.694.500
   PubMed Web of Science ®Google Scholar
• Minegishi Y, Ohmatsu H, Miyamoto T, et al. Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study. Eur J Cancer. 2004;40(8):1188–1192. doi: 10.1016/j.ejca.2004.01.027
   PubMed Web of Science ®Google Scholar
• Henzi I, Sonderegger J, Tramèr MR. Efficacy, dose-response, and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can J Anesth/J Can Anesth. 2000;47(6):537–551. doi: 10.1007/BF03018945
   PubMed Web of Science ®Google Scholar
• Jackson C, Sheehan A, Reddan J. Evidence-based Review of the Black-box Warning for Droperidol. Am J Health-System Pharm. 2007;64(11):1174–1186. doi: 10.2146/ajhp060505
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Talk Paper: FDA Strengthens Warnings for Droperidol. Pub. No. T01-62. [2001 Dec 5].
   Google Scholar
• Calver L, Isbister GK. Parenteral sedation of elderly patients with acute behavioral disturbance in the ED. Am J Emerg Med. 2013;31(6):970–973. doi: 10.1016/j.ajem.2013.03.026
   PubMed Web of Science ®Google Scholar
• Storrar J, Hitchens M, Platt T, et al. Droperidol for treatment of nausea and vomiting in palliative care patients. Cochrane Database Syst Rev. 2014;11(5):CD006938. doi: 10.1002/14651858.CD006938.pub3
   Google Scholar
• Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007;102(9):2036–2045. doi: 10.1111/j.1572-0241.2007.01255.x
   PubMed Web of Science ®Google Scholar
• Ward BA, Morocho A, Kandil A, et al. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004;58(3):277–287. doi: 10.1111/j.1365-2125.2004.02156.x
   PubMed Web of Science ®Google Scholar
• Meuldermans W, Hurkmans R, Swysen E, et al. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Pharmacokinet. 1981;6(1):49–60. doi: 10.1007/BF03189515
   PubMedGoogle Scholar
• Braun M, Cawello W, Boekens H, et al. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br J Clin Pharmacol. 2009;67(2):209–215. doi: 10.1111/j.1365-2125.2008.03334.x
   PubMed Web of Science ®Google Scholar
• Heykants J, Hendriks R, Meuldermans W, et al. On the pharmacokinetics of domperidone in animals and man IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Pharmacokin. 1981;6(1):61–70. doi: 10.1007/BF03189516
   PubMedGoogle Scholar
• Takahashi T, Kurosawa S, Wiley JW, et al. Mechanism for the gastrokinetic action of domperidone Vitro Stud In Guin Pigs. Gastroenterol. 1991;101(3):703–710. doi: 10.1016/0016-5085(91)90528-S
   PubMed Web of Science ®Google Scholar
• Sanger GJ, Andrews PLR. Review article: an analysis of the pharmacological rationale for selecting drugs to inhibit vomiting or increase gastric emptying during treatment of gastroparesis. Aliment Pharmacol Ther. 2023;57(9):962–978. doi: 10.1111/apt.17466
   PubMed Web of Science ®Google Scholar
• Huys J. Cytostatic-associated vomiting effectively inhibited by domperidone (R 33 812). Cancer Chemother Pharmacol. 1978;1(4):215–218. doi: 10.1007/BF00257152
   PubMed Web of Science ®Google Scholar
• Cunningham D, Evans C, Claude GJ, et al. Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. BMJ. 1987;295(6592):250. doi: 10.1136/bmj.295.6592.250
   PubMedGoogle Scholar
• Roila F, Tonato M, Basurto C, et al. Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.V. CMF Eur J Cancer Clin Oncol. 1987;23(6):615–617. doi: 10.1016/0277-5379(87)90255-0
   PubMedGoogle Scholar
• Junqueira DR, Bennett D, Huh SY, et al. Risk of adverse events associated with Domperidone and metoclopramide in gastroparesis: systematic review and meta-analysis. Drugsin R and D. 2023;23(1):1–20. doi: 10.1007/s40268-023-00413-x
   PubMed Web of Science ®Google Scholar
• Stoetzer C, Voelker M, Doll T, et al. Cardiotoxic Antiemetics Metoclopramide and domperidone block cardiac voltage-gated Na+ channels. Anesth Analg. 2017;124(1):52–60. doi: 10.1213/ANE.0000000000001673
   PubMed Web of Science ®Google Scholar
• Ou LB, Moriello C, Douros A, et al. Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: a systematic review and meta-analysis of observational studies. Br J Clin Pharmacol. 2021;87(10):3649–3658. doi: 10.1111/bcp.14737
   PubMed Web of Science ®Google Scholar
• Rhew K, Han N, Oh JM. Impact of safety warning on domperidone prescribing for geriatric patients in South Korea: Analysis of National Insurance Claim Data. Int J Environ Res Public Health. 2019;16:2985. doi: 10.3390/ijerph16162985
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. CMDH confirms recommendations on restricting use of domperidone-containing medicines. 2014 Apr 25 [cited 2024 Jun 20]. Available from: https://www.ema.europa.eu/en/news/cmdh-confirms-recommendations-restricting-use-domperidone-containing-medicines#:~:text=The%20CMDh%20confirmed%20by%20majority,by%20mouth%20for%20adults%20and
   Google Scholar
• Hale AS. Olanzapine. Br J Hosp Med. 1997;58(9):442–445.
   PubMedGoogle Scholar
• Chow R, Herrstedt J, Aapro M, et al. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021;29(7):3439–3459. doi: 10.1007/s00520-020-05935-7
   PubMed Web of Science ®Google Scholar
• Harder S, Grønvold M, Isaksen J, et al. Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study. Support Care Cancer. 2019;27(8):2849–2856. doi: 10.1007/s00520-018-4593-3
   PubMed Web of Science ®Google Scholar
• Thomas K, Saadabadi A. Olanzapine. In: StatPearls. Treasure Island (FL). Statpearls Publishing; 2023.
   Google Scholar
• Bymaster FP, Hemrick-Luecke SK, Perry KW, et al. Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, α1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology. 1996;124(1–2):87–94. doi: 10.1007/BF02245608
   PubMed Web of Science ®Google Scholar
• Barak N, Beck Y, Albeck JH. Betahistine decreases olanzapine-induced weight gain and somnolence in humans. J Psychopharmacol. 2016;30(3):237–241. doi: 10.1177/0269881115626349
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT and 5-HT receptors by olanzapine. Eur J Pharmacol. 2001;430(2–3):341–349. doi: 10.1016/S0014-2999(01)01399-1
   PubMed Web of Science ®Google Scholar
• Zhang X-L, Ying J-E. Olanzapine for the prevention and treatment of chemotherapy-induced nausea and vomiting: a review to identify the best way to administer the drug. Curr Oncol. 2022;29(11):8235–8243. doi: 10.3390/curroncol29110650
   PubMed Web of Science ®Google Scholar
• Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134–142. doi: 10.1056/NEJMoa1515725
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(2):242–249. doi: 10.1016/S1470-2045(19)30678-3
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yang Y, Gao F, et al. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of olanzapine plus triple antiemetic regimen for the prevention of multiday highly emetogenic chemotherapy-induced nausea and vomiting (OFFER study). EClinicalMedicine. 2022;55:101771. doi: 10.1016/j.eclinm.2022.101771
   PubMedGoogle Scholar
• Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21(6):1655–1663. doi: 10.1007/s00520-012-1710-6
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Herrstedt J, Clark-Snow R, et al. updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple‑day chemotherapy, high‑dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 2024;2023;32(1):36. doi: 10.1007/s00520-023-08224-1
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38(24):2782–2797. doi: 10.1200/JCO.20.01296
   PubMed Web of Science ®Google Scholar
• Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686–1696. doi: 10.1176/ajp.156.11.1686
   PubMed Web of Science ®Google Scholar
• Malhotra K, Vu P, Wang DH, et al. Olanzapine-Induced Neutropenia. Ment Illn. 2015;7(1):18–20. doi: 10.1108/mi.2015.5871
   Google Scholar
• Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9(5):188–195. doi: 10.1016/j.suponc.2011.05.002
   PubMedGoogle Scholar
• Tan L, Liu J, Liu X, et al. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp And Clin Cancer Res. 2009;28(1):1–7. doi: 10.1186/1756-9966-28-131
   PubMedGoogle Scholar
• Mizukami N, Yamauchi M, Koike K, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage. 2014;47(3):542–550. doi: 10.1016/j.jpainsymman.2013.05.003
   PubMed Web of Science ®Google Scholar
• Sutherland A, Naessens K, Plugge E, et al. Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults. Cochrane Database Syst Rev. 2018;9: CD012555. (9). doi: 10.1002/14651858.CD012555
   PubMedGoogle Scholar
• Ithimakin S, Theeratrakul P, Laocharoenkiat A, et al. Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy. Support Care Cancer. 2020;28(11):5335–5342. doi: 10.1007/s00520-020-05380-6
   PubMed Web of Science ®Google Scholar
• Sukauichai S, Ketkaew C, Othaganont N, et al. Efficacy of olanzapine 5 mg versus 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting in patients receiving high emetic risk chemotherapy without neurokinin-1 receptor antagonist. Asian Pac J Cancer Prev. 2022;23(6):2137–2143. doi: 10.31557/APJCP.2022.23.6.2137
   PubMedGoogle Scholar
• Jakobsen JN, Herrstedt J. Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients. Crit Rev Oncol Hematol. 2009;71(3):214–221. doi: 10.1016/j.critrevonc.2008.12.006
   PubMed Web of Science ®Google Scholar
• Bajpai J, Kapu V, Rath S, et al. Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol. 2024;25(2):246–254. doi: 10.1016/S1470-2045(23)00628-9
   PubMed Web of Science ®Google Scholar
• Andrews PLR, Sanger GJ. Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol. 2014;722:108–121. doi: 10.1016/j.ejphar.2013.09.072
   PubMed Web of Science ®Google Scholar